These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21648229)

  • 21. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux].
    Aguirre C; Haramburu F
    Therapie; 1995; 50(6):563-9. PubMed ID: 8745957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 23. The quantification of drug risks in practice.
    Lee D; Bergman U
    WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852
    [No Abstract]   [Full Text] [Related]  

  • 24. Improving adverse drug reaction reporting in the community setting.
    McCloskey BA
    Med Interface; 1996 May; 9(5):85-7. PubMed ID: 10157690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MedWatch: the new medical products reporting program.
    Couig MP; Merkatz RB
    Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
    [No Abstract]   [Full Text] [Related]  

  • 26. MedWatch. On lookout for medical product problems.
    Ropp KL
    FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
    [No Abstract]   [Full Text] [Related]  

  • 27. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The monitoring of adverse events following immunization.
    Tatley M
    N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 33. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
    van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
    Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
    Hauben M; Vegni F; Reich L; Younus M
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunization: adverse event reporting system].
    Weil-Olivier C; Jacquet A
    Arch Pediatr; 2006 Jun; 13(6):646-8. PubMed ID: 16697590
    [No Abstract]   [Full Text] [Related]  

  • 37. [Good practices in pharmacovigilance. Drugs for human use].
    Therapie; 1995; 50(6):547-55. PubMed ID: 8745955
    [No Abstract]   [Full Text] [Related]  

  • 38. [Importance and value of drug monitoring in medical practice].
    Schmitt J
    Bull Soc Sci Med Grand Duche Luxemb; 1995; 132(3):35-7. PubMed ID: 8665624
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatitis B vaccination and multiple sclerosis: a data mining perspective.
    Hauben M; Sakaguchi M; Patadia V; M Gerrits C
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):943-5. PubMed ID: 17636551
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.